Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir vs Lopinavir/Ritonavir in Moderate COVID-19
NCT04376814Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoints: Mortality at 28 days, Length of Hospitalization at 28 days and 5 more. Started Mar 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04376814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04376814.